We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Mereo BioPharma

Merger with NASDAQ-listed OncoMed

Lighthouse | 07 December 2018


New insights from Parkinson’s disease collaboration

Update | 06 December 2018


Momentum building in Cell Therapy and CARMA

Outlook | 05 December 2018


Opening new pathways in immuno-oncology

Initiation | 28 November 2018


Advancing towards randomised studies

Update | 26 November 2018


Key CERTiFy study confirms CERAMENT’s properties

Update | 19 November 2018

Tissue Regenix Group

Arthrex collaboration extended into Europe

Update | 13 November 2018


Extension of clinical and commercial license with CRISPR Therapeutics

Lighthouse | 09 November 2018


Stronger commercial platform to make strategic inroads

Update | 08 November 2018

Mereo BioPharma

Phase II starts with backing from patient support group

Lighthouse | 05 November 2018
1 2 3 4 5 6 7 8 9 10 11
105 results found.